Vertex, Crispr’s Casgevy Accused of Infringing New ToolGen Patent

ToolGen Inc. accused Vertex Pharmaceuticals Inc., Crispr Therapeutics Inc., and several manufacturing partners of infringing its newly issued gene-editing patent in making Casgevy, a multimillion-dollar treatment for serious inherited blood disorders.

Boston-based Vertex and Switzerland-based Crispr Therapeutics produce Casgevy, which treats sickle cell disease and transfusion-dependent beta-thalassemia, using a method claimed in US Patent No. 12,473,559, according to a complaint filed Tuesday in the US District Court for the District of Massachusetts. Manufacturing partners including Lonza Group AG, Charles River Laboratories Inc., Roslin Cell Therapies Ltd., and Biomay AG also are defendants.

The patent covers a ...